Product Name: PDGFRB (66-80)
Product Number: PE-01BBX99
Size: 200 µg      Price:51.00
1 mg      $US102.00
5 mg      224.00
Peptide Name: PDGFRB (66-80)

Product Use: Services as a blocking peptide for use with the PDGFRB-4 rabbit polyclonal antibody (Cat. No.: AB-NK243-3) that is also available from Kinexus. The peptide sequence is located in the N-terminus.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: CSQEPPQEMAKAQDGT

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 1718.8 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: PDGFRB pan-specific antibody (Cat. No.: AB-NK243-3)

Scientific Background: PDGFRB is a receptor protein-tyrosine kinase in the TK family and PDGFR group. It acts as a cell surface receptor for PDGFA, PDGFB, and PDGFC. It is highly expressed and widely distributed in most tested human tissues. Orthologues are highly conserved in mammals and birds. PDGFRB is activated by binding platelet-derived growth factor. Autophosphorylation of Y579, Y581, Y716, Y740 and Y751 increases PDGFRB kinase activity. Protein interactions are induced with phosphorylation of Y716 (with Grb2 & Grb7), Y579 (with PIK3R1, PLCg1, RasGAP, Shc1 & Src), Y581 (with PIK3R1, PLCg1, RasGAP & Src), Y740 and Y751 (with PIK3C2A, PIK3CA, PIK3R1 & Shc1), Y763 (with SHP2), Y771 (with RasGAP and Shc1), Y775 (with Grb7), Y1009 (with Cbl, PLCg1, SH3KBP1 & SHP2), and Y1021 (with PLCg1). Phosphorylation of Y1009 inhibits binding to PIK3R1 and RasGAP. PDGFRb-deficient mice are hemorrhagic, severely anemic and exhibit a defect in kidney glomeruli function. PDGFRb expression and activity is elevated in several cancers and inhibition of PDGFRb activity blocks progression of renal carcinoma in an animal model. The active form of the protein kinase normally acts to promote tumour cell proliferation. R561C and P660T mutations in PDGFRB are associated with myofibromatosis, infantile 1. A translocation between chromosomes 5 and 12 that fuses this gene to that of the translocation, results in chronic myeloproliferative disorder with eosinophilia. PDGFRB has also been linked with myeloproliferative disorders, metastatic medulloblastomas, breast carcinomas and gastric adenocarcinomas. Insertional mutagenesis studies in mice also support a role for this protein kinase in mouse cancer oncogenesis.